AdvisorShares Investments LLC Has $456,000 Stock Position in Neuronetics, Inc. $STIM

AdvisorShares Investments LLC boosted its position in Neuronetics, Inc. (NASDAQ:STIM) by 8.3% in the 2nd quarter, according to its most recent filing with the SEC. The fund owned 130,534 shares of the company’s stock after purchasing an additional 10,000 shares during the period. AdvisorShares Investments LLC owned about 0.20% of Neuronetics worth $456,000 as of its most recent filing with the SEC.

Several other hedge funds have also bought and sold shares of the company. Goldman Sachs Group Inc. lifted its stake in Neuronetics by 2,993.3% in the 1st quarter. Goldman Sachs Group Inc. now owns 630,393 shares of the company’s stock valued at $2,320,000 after purchasing an additional 610,014 shares during the last quarter. Ghisallo Capital Management LLC acquired a new stake in Neuronetics in the 1st quarter valued at about $1,472,000. CenterBook Partners LP acquired a new stake in Neuronetics in the 1st quarter valued at about $1,200,000. Cubist Systematic Strategies LLC acquired a new stake in Neuronetics in the 1st quarter valued at about $1,055,000. Finally, AWM Investment Company Inc. acquired a new stake in Neuronetics in the 1st quarter valued at about $905,000. 53.59% of the stock is currently owned by institutional investors and hedge funds.

Neuronetics Stock Down 6.9%

NASDAQ STIM opened at $2.70 on Friday. The company has a 50 day moving average of $3.00 and a 200-day moving average of $3.61. The company has a market cap of $178.52 million, a price-to-earnings ratio of -2.39 and a beta of 1.17. The company has a current ratio of 2.02, a quick ratio of 1.84 and a debt-to-equity ratio of 1.76. Neuronetics, Inc. has a 1-year low of $0.52 and a 1-year high of $5.92.

Neuronetics (NASDAQ:STIM) last announced its quarterly earnings data on Tuesday, August 5th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.07). The firm had revenue of $38.11 million during the quarter, compared to the consensus estimate of $36.80 million. Neuronetics had a negative net margin of 43.47% and a negative return on equity of 156.36%. Neuronetics has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. On average, equities research analysts expect that Neuronetics, Inc. will post -1.13 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts have issued reports on STIM shares. Weiss Ratings restated a “sell (e+)” rating on shares of Neuronetics in a research report on Wednesday, October 8th. Canaccord Genuity Group dropped their target price on Neuronetics from $8.00 to $7.00 and set a “buy” rating for the company in a report on Wednesday, August 6th. One research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Neuronetics has an average rating of “Hold” and a consensus price target of $7.00.

About Neuronetics

Neuronetics, Inc, a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder.